Histone deacetylase 6 functions as a tumor suppressor by activating c-Jun NH2-terminal kinase-mediated beclin 1-dependent autophagic cell death in liver cancer

Hepatology

Volumn 56, Issue 2, 2012, Pages 644-657

  Jung, Kwang Hwa ^a   Noh, Ji Heon ^a   Kim, Jeong Kyu ^a   Eun, Jung Woo ^a   Bae, Hyun Jin ^a   Chang, Young Gyoon ^a   Kim, Min Gyu ^a   Park, Won Sang ^a   Lee, Jung Young ^a   Lee, Sang Yeop ^b   Chu, In Sun ^b   Nam, Suk Woo ^a  

^a The Catholic University of Korea   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BECLIN 1; HISTONE DEACETYLASE 6; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; AUTOPHAGY; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL CYCLE ARREST; CELL DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECURRENCE FREE SURVIVAL; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HEP G2 CELLS; HISTONE DEACETYLASES; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROGNOSIS; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS;

EID: 84864362949     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25699     Document Type: Article

References (27)

1. Ahn J, Flamm SL. Hepatocellular carcinoma. Dis Mon 2004; 50: 556-573.
2. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 2005; 25: 212-225.
3. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004; 5: 215-219.
4. Shen YC, Hsu C, Cheng AL. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol 2010; 45: 794-807.
5. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 2003; 983: 84-100.
6. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008; 9: 206-218.
7. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett 2009; 277: 8-21.
8. Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007; 26: 5310-5318.
9. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002; 417: 455-458.
10. Lee JY, Koga H, Kawaguchi Y, Tang W, Wong E, Gao YS, et al. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J 2010; 29: 969-980.
11. Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y, Barrientos T, et al. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res 2008; 68: 7561-7569.
12. Shan B, Yao TP, Nguyen HT, Zhuo Y, Levy DR, Klingsberg RC, et al. Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition. J Biol Chem 2008; 283: 21065-21073.
13. Sakuma T, Uzawa K, Onda T, Shiiba M, Yokoe H, Shibahara T, et al. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol 2006; 29: 117-124.
14. Rey M, Irondelle M, Waharte F, Lizarraga F, Chavrier P. HDAC6 is required for invadopodia activity and invasion by breast tumor cells. Eur J Cell Biol 2011; 90: 128-135.
15. Aldana-Masangkay GI, Sakamoto KM. The role of HDAC6 in cancer. J Biomed Biotechnol 2011; 2011: 875824.
16. Nam SW, Park JY, Ramasamy A, Shevade S, Islam A, Long PM, et al. Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. HEPATOLOGY 2005; 42: 809-818.
17. Kim SM, Leem SH, Chu IS, Park YY, Kim SC, Kim SB, et al. 65-gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. HEPATOLOGY 2011 [Epub ahead of print].
18. Kihara A, Kabeya Y, Ohsumi Y, Yoshimori T. Beclin-phosphatidylinositol 3-kinase complex functions at the trans-Golgi network. EMBO Rep 2001; 2: 330-335.
19. Chu CT, Zhu J, Dagda R. Beclin 1-independent pathway of damage-induced mitophagy and autophagic stress: implications for neurodegeneration and cell death. Autophagy 2007; 3: 663-666.
20. Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, Elazar Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J 2007; 26: 1749-1760.
21. Li DD, Wang LL, Deng R, Tang J, Shen Y, Guo JF, et al. The pivotal role of c-Jun NH2-terminal kinase-mediated Beclin 1 expression during anticancer agents-induced autophagy in cancer cells. Oncogene 2009; 28: 886-898.
22. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1: 194-202.
23. Yoshida N, Omoto Y, Inoue A, Eguchi H, Kobayashi Y, Kurosumi M, et al. Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. Cancer Sci 2004; 95: 496-502.
24. Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005; 19: 1751-1759.
25. Zhang X, Yuan Z, Zhang Y, Yong S, Salas-Burgos A, Koomen J, et al. HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell 2007; 27: 197-213.
26. Levine B. Cell biology: autophagy and cancer. Nature 2007; 446: 745-747.
27. Rosenfeldt MT, Ryan KM. The multiple roles of autophagy in cancer. Carcinogenesis 2011; 32: 955-963.